TABLE 3.
Selected and Common Comorbidities in Moderate-to-Severe PsO Patients and Matched Controls
| Moderate-to-Severe PsO Patients | Controls | P Valuea | OR (95% CI)b | P Valueb | ||||
|---|---|---|---|---|---|---|---|---|
| N = 5,492 [A] | N = 5,492 [B] | [A] vs. [B] | ~[A]/[B] | [A] vs. [B] | ||||
| Selected and common comorbidities,c n (%) | ||||||||
| Hyperlipidemia | 1,831 | (33.3) | 1,499 | (27.3) | < 0.001 | 1.3 | (1.2-1.4) | < 0.001 |
| Hypertension | 1,803 | (32.8) | 1,292 | (23.5) | < 0.001 | 1.6 | (1.4-1.7) | < 0.001 |
| Psoriatic arthritis | 1,212 | (22.1) | 0 | (0.0) | < 0.001 | NA | NA | |
| Diabetes | 867 | (15.8) | 532 | (9.7) | < 0.001 | 1.7 | (1.5-1.9) | < 0.001 |
| Depression | 497 | (9.1) | 299 | (5.4) | < 0.001 | 1.7 | (1.4-2.0) | < 0.001 |
| Coronary heart disease | 406 | (7.4) | 241 | (4.4) | < 0.001 | 1.5 | (1.2-1.8) | < 0.001 |
| Acute myocardial infarction | 41 | (0.7) | 27 | (0.5) | 0.085 | 1.3 | (0.7-2.5) | 0.474 |
| Rheumatoid arthritisd | 349 | (6.4) | 47 | (0.9) | < 0.001 | 9.9 | (6.7-14.7) | < 0.001 |
| Anxiety | 345 | (6.3) | 231 | (4.2) | < 0.001 | 1.4 | (1.2-1.7) | < 0.001 |
| Obesity | 265 | (4.8) | 124 | (2.3) | < 0.001 | 1.9 | (1.5-2.4) | < 0.001 |
| Other autoimmune disorderse | 237 | (4.3) | 80 | (1.5) | < 0.001 | 2.7 | (2.0-3.7) | < 0.001 |
| Cerebrovascular disease (stroke) | 201 | (3.7) | 100 | (1.8) | < 0.001 | 1.7 | (1.3-2.3) | < 0.001 |
| Occlusion and stenosis of precerebral arteries | 93 | (1.7) | 48 | (0.9) | < 0.001 | 1.9 | (1.2-3.0) | 0.005 |
| Skin cancer | 177 | (3.2) | 95 | (1.7) | < 0.001 | 1.9 | (1.4-2.5) | < 0.001 |
| Nonmelanoma | 165 | (3.0) | 81 | (1.5) | < 0.001 | 2.1 | (1.5-2.8) | < 0.001 |
| Peripheral vascular disease | 175 | (3.2) | 95 | (1.7) | < 0.001 | 1.6 | (1.2-2.2) | 0.002 |
| Other malignanciesf | 170 | (3.1) | 124 | (2.3) | 0.004 | 1.0 | (0.8-1.4) | 0.860 |
| Crohn’s disease or ulcerative colitisd | 135 | (2.5) | 41 | (0.7) | < 0.001 | 3.4 | (2.2-5.2) | < 0.001 |
| Multiple sclerosisd | 36 | (0.7) | 21 | (0.4) | 0.047 | 1.3 | (0.5-3.0) | 0.576 |
| Lymphoma | 32 | (0.6) | 2 | (0.0) | < 0.001 | 22.7 | (3.1-169.2) | 0.002 |
aUnivariate comparison was made using McNemar’s tests (exact binomial distribution was used if number of discordant pairs was ≤ 25).
bORs and P values were estimated using conditional logistic regression, controlling for insurance type, individual other comorbid medical conditions, and modified Charlson Comorbidity Index scores calculated excluding selected and common comorbidities in PsO. ORs greater than 1 indicate increased risk for PsO patients compared with controls.
cSelected and common comorbidities were measured during the 12-month study period.
dClassified as autoimmune diseases.
eOther autoimmune disorders included alopecia areata, celiac disease, systemic sclerosis, Sjögren’s syndrome, vitiligo, chronic urticaria, systemic lupus erythematosus, Addison’s disease, giant cell arteritis, pulmonary fibrosis, and chronic glomerulonephritis.
fOther malignancies included cancers of lung, pharynx, liver, pancreas, breast, vulva, penis, bladder, and kidney.
CI = confidence interval; NA = not applicable; OR = odds ratio; PsO = psoriasis.